Jukapun Yoodee1, Unchalee Permsuwan1, Mantiwee Nimworapan2. 1. Faculty of Pharmacy, Chiang Mai University,Suthep Road, Muang District, Chiang Mai, 50200, Thailand. 2. Faculty of Pharmacy, Chiang Mai University,Suthep Road, Muang District, Chiang Mai, 50200, Thailand. Electronic address: mantiwee@gmail.com.
Abstract
BACKGROUND: Olanzapine is an anti-psychotic drug that has been used for preventing and treating Chemotherapy-Induced Nausea and Vomiting (CINV). This study aimed to systematically review and meta-analyze the efficacy and safety of olanzapine for prophylaxis and treatment of CINV. METHODS: We conducted a systematic literature search of MEDLINE, EMBASE, SCOPUS, and the Cochrane Central Register of Controlled Trials-CENTRAL up to July 15, 2016. All observational and intervention studies were included, but only the intervention studies were pooled for meta-analysis. The efficacy outcome was the proportion of patients achieving complete response (CR) - no emesis and no rescue therapy, in the acute, delayed, and overall phases. The safety outcomes were the adverse events associated with olanzapine according to Common Terminology Criteria for Adverse Events (CTCAE). RESULTS: Sixteen studies were eligible: 15 clinical trials and 1 observational study. Nine of the interventional studies were pooled for meta-analysis. The CR of olanzapine was superior to other anti-emetic regimens, in both the delayed and overall phases (RR=1.27, 95% CI 1.07-1.49, RR=1.32, 95% CI 1.08-1.62, respectively). However, olanzapine was not better than standard CINV prophylaxis of the nausea and emesis outcome in the acute phase. Drowsiness and constipation were the most reported adverse events. No grade 3 or 4 adverse events were reported. CONCLUSION: Olanzapine is effective and safe at reducing during the delayed and overall phase of the CINV prevention. Other regimens might be added, in cases of CINV during the acute phase of CINV.
BACKGROUND:Olanzapine is an anti-psychotic drug that has been used for preventing and treating Chemotherapy-Induced Nausea and Vomiting (CINV). This study aimed to systematically review and meta-analyze the efficacy and safety of olanzapine for prophylaxis and treatment of CINV. METHODS: We conducted a systematic literature search of MEDLINE, EMBASE, SCOPUS, and the Cochrane Central Register of Controlled Trials-CENTRAL up to July 15, 2016. All observational and intervention studies were included, but only the intervention studies were pooled for meta-analysis. The efficacy outcome was the proportion of patients achieving complete response (CR) - no emesis and no rescue therapy, in the acute, delayed, and overall phases. The safety outcomes were the adverse events associated with olanzapine according to Common Terminology Criteria for Adverse Events (CTCAE). RESULTS: Sixteen studies were eligible: 15 clinical trials and 1 observational study. Nine of the interventional studies were pooled for meta-analysis. The CR of olanzapine was superior to other anti-emetic regimens, in both the delayed and overall phases (RR=1.27, 95% CI 1.07-1.49, RR=1.32, 95% CI 1.08-1.62, respectively). However, olanzapine was not better than standard CINV prophylaxis of the nausea and emesis outcome in the acute phase. Drowsiness and constipation were the most reported adverse events. No grade 3 or 4 adverse events were reported. CONCLUSION:Olanzapine is effective and safe at reducing during the delayed and overall phase of the CINV prevention. Other regimens might be added, in cases of CINV during the acute phase of CINV.
Authors: Ronald Chow; Crystal Valdez; Natalie Chow; Daniel Zhang; James Im; Emily Sodhi; Michael Lock Journal: Support Care Cancer Date: 2020-01-08 Impact factor: 3.603
Authors: J Flank; T Schechter; P Gibson; D L Johnston; A D Orsey; C Portwine; L Sung; L L Dupuis Journal: Support Care Cancer Date: 2017-08-30 Impact factor: 3.603
Authors: Marcelo Soares Fernandes; Fernanda Barbisan; Verônica Farina Azzolin; Pedro Antônio Schmidt do Prado-Lima; Cibele Ferreira Teixeira; Ivo Emílio da Cruz Jung; Charles Elias Assmann; Rogerio Tomasi Riffel; Marta Maria Medeiros Frescura Duarte; Ednea Maia Aguiar-Ribeiro; Ivana Beatrice Mânica da Cruz Journal: PLoS One Date: 2019-01-29 Impact factor: 3.240
Authors: Ronald Chow; Jørn Herrstedt; Matti Aapro; Leonard Chiu; Henry Lam; Elizabeth Prsic; Michael Lock; Carlo DeAngelis; Rudolph M Navari Journal: Support Care Cancer Date: 2021-01-13 Impact factor: 3.359
Authors: Gabriel Tavares Garcia; Robson Fonseca Ribeiro; Isabella Boechat Faria Santos; Fabiana de Campos Gomes; João Simão de Melo-Neto Journal: Med Acupunct Date: 2021-02-16